文献速递慢性静脉疾病

专用静脉支架与标准复合Wallstent-Z支架用于髂股静脉支架置入的比较:中期结局

Comparison between a dedicated venous stent and standard composite Wallstent-Z stent approach to iliofemoral venous stenting: Intermediate-term outcomes.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-07-21

本研究回顾性比较了Bard Venovo专用静脉支架与Wallstent-Zenith复合支架用于症状性慢性髂股静脉阻塞的167例患者(167条肢体)的中期结局。两组在静脉临床严重程度评分、肿胀分级、生活质量改善及18个月支架通畅率方面无显著差异,疼痛视觉模拟评分在复合组改善更优(P=0.007)。作者认为两种支架的临床结局、生活质量改善和支架通畅率相当,但需进一步研究确认长期效果。

要点

  • Bard Venovo支架与Wallstent-Z复合支架在静脉临床严重程度评分和肿胀分级改善上无显著差异。
  • 疼痛视觉模拟评分在复合支架组改善更优(P=0.007)。
  • 18个月一期、一期辅助、二期通畅率两组无显著差异(P>0.4)。

核心结论

  • 对于因生活质量受损的慢性髂股静脉阻塞而接受支架置入的患者,Bard Venovo静脉支架在临床结局、生活质量改善和支架通畅率方面与Wallstent-Z复合支架配置相当。
  • 然而,需要进一步研究以确认长期改善。

研究设计与样本

  • 回顾性审查2019年至2020年间因保守治疗失败且生活质量受损的慢性髂股静脉阻塞而首次置入髂股静脉支架的167例患者(167条肢体)的同期录入电子病历数据。
  • 比较Bard Venovo支架组与匹配的Wallstent-Zenith复合支架组肢体。

主要发现

  • 6个月时,单侧Venovo支架组静脉临床严重程度评分从7改善至4,复合Wallstent-Z支架组从5改善至4(P=0.9)。
  • 6个月时,单侧Venovo支架组肿胀分级从3改善至1,复合组从3改善至1(P=0.6)。
  • 6个月时,单侧Venovo支架组疼痛视觉模拟评分从7改善至2,复合组从5改善至0(P=0.007)。
  • 12个月时,单侧Venovo支架组溃疡愈合率为53%(8/15),复合组为56%(5/9)(P=0.7)。
  • 20项慢性静脉功能不全生活质量问卷总体评分在单侧Venovo支架组从58改善至28,复合组从59改善至40(P=0.6)。

关键数值与推荐

  • 18个月累积一期、一期辅助和二期通畅率在单侧Venovo支架组分别为81%、97%和98%,在复合组分别为87%、98%和100%(P>0.4)。
  • 两组再干预率无差异(P=0.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以确认长期改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dedicated venous stents have not been used in the management of symptomatic chronic iliofemoral venous obstruction (CIVO) until recently. The Bard Venovo stent (Becton, Dickinson, and Co, Franklin Lakes, NJ) is one such stent noted to have an increased chronic outward force and radial resistive force compared with the Wallstent (Boston Scientific, Marlborough, MA). In the present study, we evaluated the outcomes following the use of the Bard Venovo stent vs a matched cohort of limbs that had undergone stenting with the Wallstent-Zenith (Z) stent (Cook Medical Inc, Bloomington, IN) composite configuration. METHODS: A review of contemporaneously entered electronic medical record data for 167 patients (167 limbs) with initial iliofemoral stents placed from 2019 to 2020 for quality of life (QOL)-impairing CIVO that had failed conservative therapy was performed. The visual analog scale for pain score (score, 0-10), grade of swelling (score, 0-4), venous clinical severity score (score, 0-27), and the 20-item chronic venous insufficiency quality of life questionnaire instrument for QOL were evaluated before and after intervention to assess the effects of stenting. A Kaplan-Meier analysis was used to examine primary, primary-assisted and secondary stent patency, and analysis of variance with repeated measures was used to compare clinical outcomes. RESULTS: A total of 167 limbs had undergone Bard Venovo stenting (56 men and 111 women). Their median age was 61 years. The laterality was right and left in 70 and 97 limbs, respectively. Post-thrombotic syndrome was seen in 84 limbs and nonthrombotic iliac vein lesions/May-Thurner syndrome in 83 limbs. At 6 months, the venous clinical severity score had improved from 7 to 4 in the limbs with a unilateral Venovo (UV) stent and from 5 to 4 in the composite Wallstent-Z stent group (P = .9). The grade of swelling had improved from 3 to 1 in the UV group and from 3 to 1 in the composite group (P = .6), and the visual analog scale for pain score had improved from 7 to 2 in the UV group and from 5 to 0 in the composite group (P = .007). At 12 months, ulcers had healed in 53% (8 of 15) of the UV group and 56% (5 of 9) of the composite group (P = .7). The global 20-item chronic venous insufficiency quality of life questionnaire scores had improved from 58 to 28 in the UV group and from 59 to 40 in the composite group (P = .6). The cumulative primary, primary-assisted, and secondary patency at 18 months was 81%, 97%, and 98% in the UV group and 87%, 98%, and 100% in the composite group, respectively (P > .4). No difference in the reintervention rates was noted between the two groups (P = .5). CONCLUSIONS: For patients who had undergone stenting for QOL-impairing CIVO, the results with the Bard Venovo venous stent were comparable to those with the composite Wallstent-Z stent configuration for clinical outcomes, QOL improvement, and stent patency. Further study is, however, required to confirm this improvement in the long term.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Powell T, Raju S, Jayaraj A, et al. Comparison between a dedicated venous stent and standard composite Wallstent-Z stent approach to iliofemoral venous stenting: Intermediate-term outcomes. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35872144. doi:10.1016/j.jvsv.2022.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。